Dupont Capital Management Corp boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 79.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,981 shares of the company’s stock after buying an additional 19,885 shares during the quarter. Eli Lilly and Company makes up about 2.1% of Dupont Capital Management Corp’s holdings, making the stock its 11th largest position. Dupont Capital Management Corp’s holdings in Eli Lilly and Company were worth $24,161,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its stake in Eli Lilly and Company by 1.9% during the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock valued at $15,888,300,000 after buying an additional 642,274 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Eli Lilly and Company by 533,336.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock valued at $8,938,609,000 after purchasing an additional 19,056,108 shares in the last quarter. Geode Capital Management LLC raised its position in Eli Lilly and Company by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 15,205,501 shares of the company’s stock worth $7,111,568,000 after purchasing an additional 338,077 shares during the period. Morgan Stanley increased its holdings in shares of Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the period. Finally, Norges Bank bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $3,416,206,000. 81.38% of the stock is currently owned by institutional investors.
Insider Activity
In other news, major shareholder Lilly Endowment Inc sold 14,388 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the completion of the sale, the insider now owns 99,754,422 shares of the company’s stock, valued at approximately $62,873,217,098.16. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CAO Donald A. Zakrowski sold 670 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the transaction, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the sale, the insider now directly owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.
Eli Lilly and Company Stock Performance
Shares of LLY traded up $2.80 during mid-day trading on Wednesday, hitting $628.28. 1,108,195 shares of the company traded hands, compared to its average volume of 3,357,155. The stock has a market cap of $596.43 billion, a price-to-earnings ratio of 113.31, a P/E/G ratio of 2.01 and a beta of 0.31. The stock has a 50-day moving average price of $590.62 and a two-hundred day moving average price of $549.36. Eli Lilly and Company has a 1 year low of $309.20 and a 1 year high of $637.05. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.82 and a current ratio of 1.05.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.18. The business had revenue of $9.50 billion during the quarter, compared to analyst estimates of $8.88 billion. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. Equities analysts anticipate that Eli Lilly and Company will post 6.6 earnings per share for the current year.
Eli Lilly and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, March 4th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.30 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and Company’s payout ratio is currently 81.88%.
Analyst Ratings Changes
A number of brokerages have commented on LLY. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Wednesday, November 8th. UBS Group reiterated a “buy” rating and set a $710.00 price target (up from $612.00) on shares of Eli Lilly and Company in a report on Friday, October 20th. TheStreet lowered shares of Eli Lilly and Company from a “b” rating to a “c+” rating in a report on Monday, December 4th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $615.00 to $650.00 and gave the company an “overweight” rating in a research note on Monday, October 9th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $583.24.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.